Botanix Pharmaceuticals Ltd (BOT)

Currency in AUD
0.01000
0.00000(0.00%)
Closed·
Earnings results expected in 13 days
BOT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.009000.01000
52 wk Range
0.008000.15000
Key Statistics
Bid/Ask
0.009 / 0.01
Prev. Close
0.01
Open
0.01
Day's Range
0.009-0.01
52 wk Range
0.008-0.15
Volume
2.69M
Average Volume (3m)
8.61M
1-Year Change
-91.6667%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BOT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.44000
Upside
+4,300.00%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.44000
(+4,300.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Hold0.01-0.14DowngradeOct 27, 2026
Canaccord
Buy0.14+1,300.00%0.21MaintainApr 20, 2026
Canaccord Genuity
Buy0.21+2,000.00%0.24MaintainJan 28, 2026

Botanix Pharmaceuticals Ltd Earnings Call Summary for Q1/2027

  • Botanix Q1 revenue flat at $10.1M despite 32% prescription growth; gross-to-net yield fell to 21% due to weak prior authorization processing.
  • Company cut headcount 60% and operating expenses 50% while targeting 75% revenue retention; cash outflow improved to $9.2M from $10.6M prior quarter.
  • Management projects Q3 operating cash outflow of $3.6M post-restructuring, targeting 30-40% gross-to-net yield through improved PA submission rates.
  • Shares fell 3.85% to $0.013, near 52-week low, as investors weighed prescription momentum against continued cash burn and reimbursement challenges.
  • Executives forecast breakeven possible with AUD 6M quarterly revenue from commercial product; no further manufacturing spend planned for rest of FY2027.
Last Updated: 2026-10-26, 08:50 p/m
Read Full Transcript

Earnings

Latest Release
Aug 26, 2026
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
10.1M / 10.66M
EPS Revisions
Last 90 days

BOT Income Statement

Compare BOT to Peers and Sector

Metrics to compare
BOT
Peers
Sector
Relationship
P/E Ratio
−0.4x−5.3x−0.2x
PEG Ratio
−0.01−0.110.00
Price/Book
0.4x3.7x2.6x
Price / LTM Sales
0.8x7.3x2.7x
Upside (Analyst Target)
-122.1%69.6%
Fair Value Upside
Unlock−2.5%11.7%Unlock

Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.

Employees
11
Market
Australia

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
48.35M1.75%386.79K
Other Institutional Investors
491.56M17.79%3.93M
Public Companies & Retail Investors
2.22B80.46%17.78M
Total
2.76B100.00%22.1M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Copia Investment Partners Ltd5.17%142,700,0001,142
Chester Asset Management Pty Ltd3.22%88,850,154711

FAQ

What Is the Botanix (BOT) Stock Price Today?

The Botanix stock price today is 0.01000 AUD.

What Stock Exchange Does Botanix Trade On?

Botanix is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Botanix?

The stock symbol for Botanix is "BOT."

What Is the Botanix Market Cap?

As of today, Botanix market cap is 27.63000M AUD.

What Is Botanix's Earnings Per Share (TTM)?

The Botanix EPS (TTM) is -0.032.

When Is the Next Botanix Earnings Date?

Botanix will release its next earnings report on Dec 02, 2026.

From a Technical Analysis Perspective, Is BOT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Botanix Stock Split?

Botanix has split 1 times.

How Many Employees Does Botanix Have?

Botanix has 11 employees.

What is the current trading status of Botanix (BOT)?

As of Nov 19, 2026, Botanix (BOT) is trading at a price of 0.01000 AUD, with a previous close of 0.01000 AUD. The stock has fluctuated within a day range of 0.00900 AUD to 0.01000 AUD, while its 52-week range spans from 0.00800 AUD to 0.15000 AUD.

What Is Botanix (BOT) Price Target According to Analysts?

The average 12-month price target for Botanix is 0.44000 AUD, with a high estimate of 1 AUD and a low estimate of 0.01 AUD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +4,300.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.